Home > Healthcare > Biotechnology > Biotechnology R&D > Mycoplasma Testing Market

Mycoplasma Testing Market Trends

  • Report ID: GMI8300
  • Published Date: Feb 2024
  • Report Format: PDF

Mycoplasma Testing Market Trends

The growing advancements in cell line development technology are notably boosting mycoplasma testing, providing enhanced sensitivity, quicker detection, and fewer false positives. By refining cell culture techniques, cultures are becoming cleaner and more resilient, lowering the likelihood of mycoplasma contamination. Therefore, this is heightening the sensitivity of mycoplasma testing, enabling the detection of even minimal contamination levels.

  • These advancements facilitate more reliable identification of mycoplasma contamination in cell cultures, ensuring the integrity of research and biopharmaceutical production processes.
  • Furthermore, advanced cell culture systems often incorporate rapid detection methods for mycoplasma, such as PCR-based assays or automated microbial monitoring systems which include instruments such as automated cell counter which is estimated to reach USD 10.1 billion by 2032.
  • These technologies can quickly identify mycoplasma contamination, allowing for prompt remediation measures to be taken.
  • For instance, Thermo Fisher Scientific Inc.'s latest PCR-based mycoplasma detection kit, the Applied Biosystems MycoSEQ Mycoplasma Detection Kit Version 3.0, offers a rapid, sensitive, and accurate method for identifying mycoplasma contamination in cell cultures, fulfilling the criteria set forth by regulatory authorities.
  • Thus, these progressions in cell culture technology contribute to more effective and efficient mycoplasma testing, thereby bolstering the integrity and safety of cell-based products.
Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market size for mycoplasma testing was valued at around USD 909.5 Million in 2023 and is estimated to reach over USD 2.5 billion by 2032, driven by the rising contamination rate and increasing R&D activities.

Kits & reagents segment held a robust market share in 2023 and is estimated to account for USD 1.4 billion by 2032, owing to their pivotal role in mycoplasma testing, offering standardized protocols, streamlined workflows, and increased accuracy.

North America mycoplasma testing industry held a significant revenue share of 40.6% in 2023 and is predicted to witness substantial growth through 2032, driven by increasing government investment to produce new active pharmaceutical ingredients (APIs).

Becton, Dickinson, and Company (BD), Bio-Rad Laboratories, Inc., Charles River Laboratories International, Inc., Creative Bioarray, Eurofins Scientific, InvivoGen, Lonza Group AG, Merck KGaA, Minerva Biolabs GmbH, PromoCell GmbH are some of the major industry contenders.

Mycoplasma Testing Market Scope

Buy Now

Premium Report Details

  • Base Year: 2023
  • Companies covered: 13
  • Tables & Figures: 348
  • Countries covered: 22
  • Pages: 205
 Download Free Sample